Traders should monitor upcoming clinical data catalysts in 1Q 2026 for WVE-007 and WVE-006, which could drive positive sentiment despite weak financials. The strong cash position reduces near-term dilution risk, but the stock may remain volatile based on clinical trial outcomes.
Price Chart
Executive Summary
Wave Life Sciences reported a significant year-over-year decline in revenue and a shift from net income to a substantial net loss, driven by lower collaboration revenue. However, the company highlighted positive clinical progress across its pipeline, including obesity drug WVE-007 showing fat loss comparable to GLP-1s, strong data for WVE-006 in AATD, and a well-capitalized position with cash runway into 3Q 2028. The negative financials are offset by multiple upcoming clinical catalysts and pipeline advancements.
Key Financial Metrics
Key Facts
- Revenue dropped 79.7% YoY to $17.2M in Q4 2025 and 60.5% for the full year to $42.7M, primarily due to reduced GSK milestone payments.
- Net loss was $53.2M in Q4 2025 vs. $29.3M net income in Q4 2024; full-year net loss was $204.4M vs. $97.0M in 2024.
- Cash and equivalents increased to $602.1M as of Dec 31, 2025, providing runway into 3Q 2028.
- WVE-007 (obesity) showed fat loss similar to GLP-1s at three months in interim data, with muscle preservation, and plans for Phase 2a trials in 2026.
- WVE-006 (AATD) demonstrated key treatment goals met, including dynamic AAT production, with regulatory feedback on accelerated approval expected mid-2026.
- WVE-N531 (DMD) remains on track for NDA filing in 2026 for accelerated approval.
Financial Impact
Revenue declined by $66.5 million in Q4 and $65.6 million for the full year; net loss increased by $82.5 million in Q4 and $107.4 million for the full year.
Segment Breakdown
| Segment |
|---|
| obesity |
| AATD |
| DMD |
Risk Factors
- Heavy reliance on partnership revenue (GSK) creates financial volatility.
- Clinical trial failures could significantly impact the stock, given the pipeline-driven valuation.
- Dilution risk if additional funding is needed beyond 2028, though current cash runway is sufficient.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073437 |
| Document: d103046dex992.htm | 0001193125-26-073437 |
| Document: d103046d8k.htm | 0001193125-26-073437 |
| Document: 0001193125-26-073437-index-headers.html | 0001193125-26-073437 |
| Document: 0001193125-26-073437-index.html | 0001193125-26-073437 |
| Document: 0001193125-26-073437.txt | 0001193125-26-073437 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $5.41 $4.58 | ▼ −15.34% | ▼ −13.35% | $3.81 (−29.57%) |
May 18, 2026 19w ago | Press Release | $6.14 $5.95 | ▼ −3.09% | ▼ −4.08% | $3.81 (−37.95%) |
Apr 28, 2026 22w ago | 8-K | $7.52 $6.34 | ▼ −15.69% | ▼ −21.15% | $3.81 (−49.34%) |
Apr 28, 2026 22w ago | Press Release | $7.52 $6.38 | ▼ −15.16% | ▼ −20.63% | $3.81 (−49.34%) |
Apr 22, 2026 23w ago | Press Release | $7.38 $6.14 | ▼ −16.80% | ▼ −19.97% | $3.81 (−48.37%) |
Apr 15, 2026 24w ago | DEFA14A | $7.32 $6.99 | ▼ −4.51% | ▼ −10.32% | $3.81 (−47.95%) |
Apr 15, 2026 24w ago | 8-K | $7.32 $6.99 | ▼ −4.51% | ▼ −10.32% | $3.81 (−47.95%) |
Mar 26, 2026 27w ago | Press Release | $6.20 $7.18 | ▲ +15.81% | ▲ +5.14% | $3.81 (−38.55%) |
Feb 26, 2026 31w ago | 8-K | $15.36 $6.20 | ▼ −59.64% | ▼ −53.23% | $3.81 (−75.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access